Search clinical trials for: Hepatic Arterial Infusion Chemotherapy (HAIC) Combine Lenvatinib and Durvalumab (HILL)

Total 49 results

Sun Yat-sen University

Recruiting

The Efficacy of Hepatic Arterial Infusion Chemotherapy (HAIC) Combine Lenvatinib and Durvalumab (HILL) in Advanced Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma

China
Shandong Cancer Hospital and Institute

Recruiting

First-line Treatment for Unresectable Locally Advanced Distal Cholangiocarcinoma Combining Radiotherapy and HAIC

Intrahepatic Cholangiocarcinoma

China
Peking University Cancer Hospital & Institute

Recruiting

Hepatic Arterial Infusion Chemotherapy With Fruquintinib for Colorectal Cancer Liver Metastases As Third-line Therapy

Liver Metastasis Colon Cancer | Advanced Colorectal Carcinoma

China
Sun Yat-sen University

Recruiting

Hepatic Artery Infusion Chemotherapy (HAIC) Plus Durvalumab for Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Ze-yang Ding, MD
Geneplus-Beijing Co. Ltd.; Chinese Cooperative Group of Liver Cancer (CCGLC)

Recruiting

Combined HAIC, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma (CCGLC-013)

Cholangiocarcinoma Non-resectable

China
Tongji Hospital
Geneplus-Beijing Co. Ltd.

Recruiting

Combined HAIC, Lenvatinib and Cadonilimab as Conversion Therapy for Unresectable Hepatocellular Carcinoma (CCGLC-011)

Hepatocellular Carcinoma Non-resectable

China
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Sintilimab Combined With Regorafenib and HAIC in Patients With Colorectal Liver Metastasis

Colorectal Cancer | Liver Metastasis
Harbin Medical University

Not yet recruiting

HAIC+Adebrelimab+Lenvatinib for Conversion Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer

Biliary Tract Cancer
Nanfang Hospital of Southern Medical University

Recruiting

Hepatic Arterial Infusion Combined With Lenvatinib and Camrelizumab for Unresectable Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Shi Ming

Completed

HAIC Plus Lenvatinib and Toripalimab for Advanced HCC

Hepatocellular Carcinoma

China
Sun Yat-sen University

Unknown

HAIC Plus Lenvatinib vs HAIC Plus Sorafenib for Advanced HCC

Hepatocellular Carcinoma

China
Sun Yat-sen University

Recruiting

Neoadjuvant HAIC for Resectable Hepatocellular Carcinoma Beyond Milan Criteria

Hepatocellular Carcinoma

China
Sun Yat-sen University

Completed

Phase II Trial of Sorafenib Combined With Concurrent HAIC for Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Wan-Guang Zhang

Recruiting

A Single-arm Clinical Study of HAIC Combined With Apatinib and Camrelizumab in the Treatment of Unresectable MTM HCC (CCGLC-010)

Macrotrabecular Massive Hepatocellular Carcinoma

China
Shanghai Zhongshan Hospital
Shanghai Henlius Biotech

Not yet recruiting

Combination Therapy of HAIC and HLX10 and HLX04 in HCC With Major Portal Vein Tumor Thrombosis

Hepatocellular Carcinoma With Major Portal Vein Thrombosis
Sun Yat-sen University

Recruiting

HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma

Hepatocellular Carcinoma | PD-1 Inhibitor | Lenvatinib | Hepatic Arterial Infusion Chemotherapy

China
Chen Xiaoping

Not yet recruiting

Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model

HCC
Wan-Guang Zhang
BeiGene; Geneplus-Beijing Co. Ltd.; Simcere Pharmaceutical Co., Ltd; Chinese Cooperative... and other collaborators

Recruiting

Nocardia Rubra Cell Wall Skeleton (N-CWS) Plus HAIC, Lenvatinib and Tislelizumab in Treating Patients With Advanced HCC (CCGLC-007)

Hepatocellular Carcinoma

China
Sun Yat-sen University
Second Affiliated Hospital of Guangzhou Medical University

Completed

HAIC Combined With Lenvatinib and Sintilimab for Hepatocellular Carcinoma With PVTT

Carcinoma, Hepatocellular | Liver Neoplasms | Sintilimab | Portal Vein Tumor Thrombus

China
Sun Yat-sen University

Active, not recruiting

HAIC Plus Sorafenib Versus TACE Plus Sorafenibfor Advanced HCC

Hepatocellular Carcinoma

China
Sun Yat-sen University
Guangzhou No.12 People's Hospital; Kaiping Central Hospital

Withdrawn

HAIC Plus Lenvatinib and PD-1 Antibody Versus HAIC Plus Lenvatinib for Advanced HCC

Hepatocellular Carcinoma

China
Bayer

Completed

Study to Learn More About the Potential of Antifungal Cream V61-044 Containing Trolamine to Cause Irritant Reaction of the Skin to Ultra Violet Light in Healthy Human Subjects

Dermatitis, Phototoxic

United States
Tianjin Medical University Cancer Institute and...

Recruiting

HAIC Combined With Sintilimab and Bevacizumab Biosimilar for Unresectable HCC

Hepatocellular Carcinoma

China
Sun Yat-sen University

Completed

Atezolizumab Plus Bevacizumab Versus Sintilimab Plus Bevacizumab With TACE and HAIC in Unresectable Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Huashan Hospital; The Second Affiliated Hospital of Harbin Medical University; Meng Chao Hepatobiliary Hospital of Fujian Medical University

Not yet recruiting

Hepatic Artery Infusion Chemotherapy Plus Donafenib in Patients With Hepatocellular Carcinoma After Surgery

Carcinoma | Digestive System Neoplasms | Carcinoma, Hepatocellular | Liver Neoplasms | Antineoplastic Agents | Oxaliplatin | Donafenib | Fluorouracil | Antimetabolites

China
Sun Yat-sen University

Recruiting

HAIC Plus Toripalimab vs. HAIC Plus Sorafenib for HCC With PVTT: a Non-comparative, Prospective, Randomized Trial

Hepatocellular Carcinoma

China
Sun Yat-sen University
First People's Hospital of Foshan; The First Affiliated Hospital, Guangzhou... and other collaborators

Recruiting

Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC (HAIC)

Hepatocellular Carcinoma | Chemotherapy Effect | Chemotherapeutic Toxicity

China
Sun Yat-sen University
First People's Hospital of Foshan; Guangzhou No.12 People's Hospital

Completed

HAIC Versus TACE for Large Hepatocellular Carcinoma Staged BCLC A/B.

HepatoCellular Carcinoma

China
Sun Yat-sen University

Unknown

HAIC of FOLFOX Plus Sorafenib vs HAIC of FOLFIRINOX Plus Sorafenib for Advcanced HCC

Hepatocellular Carcinoma

China
Sun Yat-sen University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Trial of Hepatic Arterial Infusion Combined With Apatinib and Camrelizumab Versus Apatinib and Camrelizumab for C-staged Hepatocellular Carcinoma in BCLC Classification (TRIPLET-III)

C-staged Hepatocellular Carcinoma in BCLC Classification

China
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

Combine Apatinib Mesylate With PD-1 Antibody SHR-1210 for HCC With High Risk of Recurrence After Radical Resection

Hepatocellular Carcinoma

China
Sun Yat-sen University
Second Affiliated Hospital of Guangzhou Medical University

Not yet recruiting

HAIC Combined With Bevacizumab and Toripalimab for Advanced Hepatocellular Carcinama

Liver Neoplasms | Hepatocellular Carcinoma | Bevacizumab | Toripalimab | Oxaliplatin
Sun Yat-sen University
First Affiliated Hospital, Sun Yat-Sen University; The First Affiliated Hospital... and other collaborators

Completed

Sorafenib Alone Versus Sorafenib Combined With HAIC for Advanced HCC

Hepatocellular Carcinoma

China
Sun Yat-sen University

Recruiting

FOLFOX-HAIC Plus Lenvatinib and Toripalimab vs. FOLFOX-HAIC Plus Lenvatinib for Advanced Hepatocellular Carcinoma: a Randomized Controlled and Double-blind Trial

Hepatocellular Carcinoma

China
Sun Yat-sen University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Trial of Hepatic Arterial Infusion Combined With Apatinib and Camrelizumab for C-staged Hepatocellular Carcinoma in BCLC Classification (TRIPLET)

C-staged Hepatocellular Carcinoma in BCLC Classification

China
Sun Yat-sen University

Completed

HAIC Plus Targeted Therapy and/or PD-1 Inhibitors for Unresectable Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma

China
Wake Forest University Health Sciences

Completed

Comparing Aquaphor to Atopiclair and EpiCeram in Children With Mild to Moderate Atopic Dermatitis

Atopic Dermatitis

United States
Sun Yat-sen University

Completed

HAIC Versus TACE for Large and Unresectable Hepatocellular Carcinoma Staged BCLC A/B

Hepatocellular Carcinoma

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Not yet recruiting

HAIC Combined With Donafenib Tosilate and Toripalimab for Unresectable HCC

Hepatocellular Carcinoma
The Central Hospital of Lishui City

Not yet recruiting

HAIC Combined With Second-line "Target Immunity" for HCC With TACE Standard Treatment Low Response or Failure

Hepatocellular Carcinoma
Hui-Chuan Sun

Recruiting

Hepatic Artery Infusion Chemotherapy for Unresectable Hepatocelluar Carcinoma Who Failed to Systemic Therapy

Hepatocellular Carcinoma

China
Kyoto University

Withdrawn

Surgery With or Without Hepatic Arterial Chemotherapy in Treating Patients With Liver Cancer

Localized Resectable Adult Primary Liver Cancer | Stage III Childhood Liver Cancer

Japan
Sun Yat-sen University
Xiangya Hospital of Central South University; Nanfang Hospital of Southern... and other collaborators

Recruiting

A Trial of Hepatic Arterial Infusion Combined With Bevacizumab and Sintilimab for Unresectable A-staged Hepatocellular Carcinoma in BCLC Classification (D-TRIPLET)

Unresectable Hepatocellular Carcinoma | Hepatocellular Carcinoma by BCLC Stage

China
Wuhan Union Hospital, China

Recruiting

Combination Therapy of HAIC, Sintilimab and Bevacizumab for Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Michael J Cavnar, MD

Terminated

Codman Catheter/Synchromed Pump Hepatic Artery Chemotherapy for Unresectable Colorectal Metastases/Intrahepatic Cholangiocarcinoma

Colorectal Neoplasms | Bile Duct Neoplasms

United States
Sun Yat-sen University

Recruiting

HAIC Plus H101 vs HAIC Alone for Unresectable HCC at BCLC A-B

Hepatocellular Carcinoma

China
Wan-Guang Zhang
The Second Affiliated Hospital of Fujian Medical University; Geneplus-Beijing... and other collaborators

Recruiting

Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma (CCGLC-001)

Hepatocellular Carcinoma Non-resectable

China
Shuhong Yi

Recruiting

Hepatic Arterial Infusion Chemotherapy in Combination With Atezolizumab and Bevacizumab for Second-line Treatment of Patients With Recurrent Liver Cancer After Liver Transplantation

Recurrent Liver Cancer After Liver Transplantation

China
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Recruiting

Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial

Metastatic Malignant Neoplasm in the Liver | Metastatic Colorectal Carcinoma | Stage IV Colorectal Cancer AJCC v8 | Unresectable Colorectal Carcinoma

United States

Search clinical trials for: Hepatic Arterial Infusion Chemotherapy (HAIC) Combine Lenvatinib and Durvalumab (HILL)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Guatemala

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations